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Abstract 
The hepatitis C virus infects more than 170 million people worldwide. Many of the HCV deaths 
have been a result of drug resistance. It is essential for researchers to continue to modify the 
molecules to create a greater variety of drug analogues, and in doing so create one that is the 
solution to the HCV epidemic. HCV drug analogs that lack a side chain are less hindered and 
more adaptable in fighting the mutant virus; drugs of this molecular form should be focused on 
to produce an optimal drug response to the virus. In the non-structural region, protease 
inhibitors are being created to directly target the virus at the specific sites where the virus is 
prone to rapid replication. MK-5172 is a drug that directly attacks HCV. Tests have been run on 
this drug and it was shown MK-5172 produces exemplary results against the drug and the drug-
resistant variants. The purpose of this project was to modify the functional groups on the MK-
5172 drug and remove the side chain ring. This was done in order for the drug to fit better 
within the substrate envelope of the virus and to minimize vulnerability to drug resistance; 
other HCV drugs without a side chain ring have shown to be more adaptable in fighting the 
mutant variants. The process of drug design by the exchange of function groups on the 
molecules is essential to eliminating harmful diseases, such as HCV. Scientists need to continue 
to work together in the drug design field to cure this problematic disease.   
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Background 
The hepatitis C virus is a rapidly expanding problem and needs to be controlled. Hepatitis C is a 
form of liver inflammation and causes a long- lasting, chronic disease. HCV is a non-cytopathic 
hepatotropic virus belonging to the Flaviviridae family; it is a spherical, enveloped virus 40-60 
nm in diameter that infects only humans and chimpanzees (UTMB, 2009). The Flaviviridae 
family consists of enveloped viruses; viral envelopes are made up of cell membranes and 
glycoproteins (UTMB, 2009). The viral substrate envelope assists HCV in entering the host cells. 
Hepatitis C is specific to the Hepacivirus subgroup. The virus is transmitted through blood by 
transfusions, hemodialysis and organ transplants. Additionally the virus can be transmitted 
though the sharing of needles making the spread of the virus more prevalent with drug abusers. 
Among people who acquired HIV through intravenous drug use in combination with the 
prevalence of HCV reaches 90%. Co-infection of the two viruses can make treatment all the 
more difficult; this would require one drug to eliminate both for maximal efficiency (Jamal, 
2006). Blood transfusions previously were a leading cause to the spread of HCV; however the 
technology associated with the practice has advanced, causing transmission of the virus to 
decrease. Dialysis patients have a higher rate of HCV infection. Possible risk factors of 
transmission are failure to disinfect devices between patients, sharing of single-use vials for 
infusions, and poor sterile technique (Jamal, 2006). The hemodialysis risk factor of transmitting 
the virus can be prevented by using proper techniques when dealing with patients; this means 
ensuring that the patients are giving a more than sterile treatment. The progression of the virus 
is acute infection then either clearance (~20 %) or chronic infection (~80 %). Following chronic 
infection is cirrhosis (~20 %) and hepatocellular carcinoma (Qureshi, 2007). Both cirrhosis and 
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hepatocellular carcinoma can be fatal. Cirrhosis is the damaging of liver cells and replacing 
them with scar tissue, eventually leading to the shutdown of the liver. Hepatocellular 
carcinoma is cancer of the liver, which leads to the spread of cancer to other organs. Since the 
virus is only present in humans and chimpanzees, it cannot be cultured actively, but a solution 
to the virus needs to be done retroactively.  This makes the process of drug design that much 
harder; the virus can be attacked directly however it cannot be studied directly therefore, 
indirect approaches are the only viable option. The virus cannot be studied directly in culture 
because of the lack of efficient viral culture systems. The virus in culture has a very narrow host 
range, which prevents it from being a useful culture system. Therefore drugs already in the 
market and in phases need to be modified for better results in efficacy and safety for the 
patients.  
HCV Genome  
The hepatitis C virus is comprised of a 9.6 kb linear single- stranded RNA genome, which 
contains 10 genes that encode for HCV. It is of positive polarity, compiled of a single 
uninterrupted open reading frame that is surrounded on either side by 5’ and 3’ un-translated 
regions and can be a template for translation or replication.  Structural genes on the 5’ region 
of the HCV genome encode a highly basic core protein (C) and two envelope proteins (E1 and 
E2), followed by the p7 gene. Then the genes that encode the non-structural proteins are NS2, 
NS3, NS4A, NS4B, NS5a and NS5B and are closer to the 3’ end (Qureshi, 2007). NS represents 
the nonstructural proteins, as shown in Figure 1. The importance in targeting the proteins is 
that NS3 specifically plays an important role in the hepatocarcinogenesis of HCV (Deng, 2006). 
The location of the NS3 protein is an essential drug target because it allows for important 
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replication and spread of the virus.  HCV is divided among six genotypes and then divided again 
into numerous subtypes. These genotypes can differ up to 30% from each other in nucleotide 
sequence and depending on the HCV genotype, length of treatment can differ greatly (Jamal, 
2006). The six genotypes are prevalent in different groups of peoples throughout the world. In 
the US patients were primarily of genotype 1, patients in China were of genotype 2 and in 
England, Thailand and India genotype 3 was most prevalent. Genotype 4 is most common in 
Africa and the Middle East, genotype 5 in South Africa and genotype 6 in south-east Asia (Jamal, 
2006). It is imperative to note that genotype 1b is less responsive to alpha-interferon therapy 
compared to genotypes 2 and 3; this makes it important to track the individual genotypes, so 
that an appropriate therapy can be made for each (Jamal, 2006). 
Protease Inhibitors 
A protease inhibitor is a type of drug that disables the enzyme protease. A substance that 
triggers chemical reactions in the body is an enzyme (Farlex, 2012).  The most successful kind of 
inhibitors used in drug design for HCV are protease inhibitors. In blocking the protease the 
replication of HCV is stunted, disabling the reproduction of the virus in new cells. In Figure 1, 
above, at the NS3 protein there is a “metalloprotease, serineprotease, RNA helicase”, which is 
an example of a protease inhibitor for HCV. Both of the drugs that have been approved for 
market are protease inhibitors.  
Pre-existing Drugs 
There are a portion of the drugs that are currently in research, phases and in the market that 
directly affect HCV, Figure 2. One of the leading drugs on the market for HCV treatment is 
Boceprevir, which is produced by Merck. Boceprevir is currently one of the only drugs that has 
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been approved and is a protease inhibitor. NS3-NS4A protease is playing a critical role in HCV 
viral replication and is therefore viewed as an ideal target for the creation of new HCV therapy 
(Njoroge, 2008). The NS3 region has been seen as an especially key location in HCV viral 
replication and is a prime location in placing an inhibitor. The difficultly arose when there were 
no viable lead structures and that the early inhibitors were designed based solely on the 
substrate-enzyme active site (Njoroge, 2008).  Working with the substrate- enzyme active site, 
Merck was eventually able to create Boceprevir. Extensive tests were performed in order to 
reach a drug capable of producing positive effects on the virus. This testing showed that 
Boceprevir, was highly selective toward the HCV serine protease; around 5 years ago it was the 
best viable option to send into drug phases (Njoroge, 2008). Now that there are more drugs in 
trial and drug design phases, Boceprevir is no longer one of the best drugs for treatment against 
HCV. However, it is still one of the only ones approved. Its efficiency needs to be improved due 
to the negative side effects of the drug which include fatigue, anemia, nausea and dysgeusia; 
these side effects are less than pleasant to experience (Merck, 2011).  Current medical forms of 
HCV include a pegylated interferon-α (PEG IFN- α) in combination with ribavirin (RBV) 
treatment in combination with the inhibitors such as Boceprevir (Rehman, 2011). This 
combination of the two, abbreviated PR is used before the inhibitor is introduced, with the 
inhibitor and at the end of treatment PR is used alone again (Merck, 2011). The problem faced 
when having the need to use both is that then the side effects from both drugs affect the 
patients. It is necessary to create a HCV drug that can be used singularly without PR that 
directly affects the virus and minimizes adverse effects. Some of the most effective antiviral 
inhibitors have focused on the following targets, which are the attempts that have been the 
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main focus so far: NS3-4A serine protease, RNA helicase activity of NS3 and NS5B RNA-
dependent RNA polymerase (Rehman, 2011).  
MK-5172 
One of Merck’s newer HCV drug inhibitors is MK-5172, Figure 3, and is currently in phase 2 of 
testing. MK-5172 is a new generation, competitive inhibitor of the HCV NS3/4a protease with a 
broad HCV genotypic activity spectrum, and it produces potent in vitro activity against viral 
variants that are resistant to other protease inhibitors in development (Levin, 2011). Multiple 
tests have been run for MK-5172 and it has shown to produce astounding results against the 
virus itself and the mutants that arise from it. In tests performed, MK-5172 demonstrated 
potent and rapid viral load reductions with 7 days of mono therapy, with 75% of patients with 
chronic GT1 infection achieved reductions in plasma HCV RNA to below the limit of possible 
study (Levin, 2011). Antiviral activity persisted for several days beyond the treatment period in 
GT1 patients, which is extremely beneficial. MK-5172 was generally well-tolerated with no 
serious adverse experiences and no discontinuations due to adverse experiences; it is key to 
lower the adverse affects (Levin, 2011). As compared to drugs currently in the market, a new 
drug, MK-5172, shown in Figure 3, producing little to no adverse effects is a serious 
improvement. If it is possible to further increase the positive effectiveness of this drug, series of 
tests should be run and the drug appropriately modified.  
MK-5172 Derivative 
Drug design is all about modifying current drugs in order to get the most useful one as possible; 
this is done by changing side groups on the molecule or changing the molecule all together to 
get the best product possible, demonstrated in Figure 4. The purpose of this product was to 
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manipulate and change the MK-5172 drug in order to make it as efficient as possible for the 
patients using it. A side group change was made in transitioning from a ring system to a chlorine 
atom. This was performed in hopes that the drug would fit better in the substrate envelope and 
then from there perform better against the multiple drug variants. Nuclear magnetic resonance 
tests were performed to ensure that the final products synthesized were in the right 
conformation and were the right products that were sought.  Further tests need to be run such 
as an enzymatic kinetic evaluation to see that the new derivative performs better against the 
drug resistant variants.  
 
 
 
 
 
 
  
 
11 
 
Methods 
Synthesis of HCV NS3/4A Protease Inhibitor MK-5172 Analogues 
Synthesis of Vinyl-ACCA-OEt and the P1-P1’ Fragment: 
  
(E)-Ethyl 2-(benzylideneamino) actetate 
 
Benzaldehyde (27.63 mL, 28.88 g, 0.27 mmol) and anhydrous sodium sulfate (19.38 g, 0.14 
mmol) were added to s suspension of glycine ethyl ester hydrochloride (38 g, 0.27 mmol) in 
tert-butylmethyl ether (TBME) (200 mL), and the mixture was cooled to 0OC. Triethylamine 
(56.88 mL, 0.41 mmol) was slowly added over the course of 30 minutes, the resulting mixture 
was stirred at 0OC for 10 minutes, warmed to room temperature and then stirred for 24 hours. 
The reaction mixture was quenched with ice-cold water (125 mL), layers were separated and 
the aqueous layer was further extracted with TBME (150 mL). The combined organic extract 
was washed with a 1:1 mixture of saturated aqueousNaHCO3 (125 mL) and NaCl (125 mL) 
solutions, dried with Na2SO4, and filtered. It was then evaporated under reduced pressure to 
provide the N-benzyl imine (50.6 g, 98.15 %) as thick yellow oil.  
(±)-(1R,2S)-Ethyl 1-((tert-butoxycarbonyl)amino)-2-vinylcyclopropanecarboxylate 
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To a suspension of lithium tert-butoxide (42.05 g, 0.503 mmol) in dry toluene (600 mL) at room 
temperature was added to a mixture of the N- benzyl imine (50.6 g, 0.265 mmol) and trans- 1,4- 
dibromo-2-butene (53.5 g, 0.25 mmol) in dry toluene (300 mL) over 90 minutes. After 15 
minutes at room temperature, the reaction was quenched by an addition of water (500 mL). 
TBME (500 mL) was added and layers were separated, the aqueous phase was further extracted 
with TBME (2 x 500 mL). The organic portion was mixed with 2 M HCl (500 mL) and the mixture 
was stirred at room temperature over –night [2 hours enough]. The organic phase was 
separated and extracted with water (400 mL). The combined aqueous phase was saturated with 
NaCl (350 g), TBME (500 mL) was added and the mixture was cooled to 0OC. The mixture was 
then basified to pH 14 by the drop-wise addition of 10 M NaOH (~ 150 mL), keeping the 
temperature below 5OC. The organic layer was separated and the aqueous phase was extracted 
with TBME (2 x 250 mL). The combine organic extract was dried, Na2SO4, filtered, and 
concentrated to a volume of 500 mL. Di-tert-butyldicarbonate (Boc2O) (57 g, 0.261 mmol) was 
added to the solution and the mixture was stirred at room temperature over the weekend. The 
reaction mixture was dried again, filtered and evaporated under reduced pressure. The 
resulting oil was purified by flash column chromatography on silica gel using a 5-20% EtOAc-
hexanes mixture as eluent to provide the racemic N-Boc- 1 –amino-2 –vinylcyclopropane 
carboxylic acid ethyl ester ( 36.93 g, 54.7%) as an off-white oil, which solidified to white 
crystalline solid while sitting in the refrigerator.  
(1R, 2S)-Ethyl 1-((tert-butoxycarbonyl)amino)-2-vinylcyclopropanecarboxylate 
 
To 1.85 L of 0.1 M phosphate buffer (pH 8.0) maintained at 40 OC was added Alcalase 2.4L 
(Novazyme) (275 mL). The temperature was brought to 38OC and the pH was adjusted to 8.0 by 
slowly adding 10 M NaOH. A solution of the racemic N-Boc- 1- amino-2- vinylcyclopropane 
carboxylic acid ethyl ester (36.9 g, 0.145 mmol) in DMSO (370 mL) was slowly added over a 
period of 90 min. The reaction temperature was the raised to 40OC, after 3 hours the pH was 
adjusted to 8.0 using the 10.0 M NaOH. The pH was adjusted periodically to 8.0 over the next 
24 hours. The reaction was then cooled to room temperature, the pH was again adjusted to 8.0, 
and stirring continued overnight. The pH was adjusted to 8.5 and the mixture was extracted 
with TBME (2 x 1L). The combined organic extract was washed with a saturated aqueous 
NaHCO3 (3 x 100 mL) and water (2 x 50 mL), dried, filtered and evaporated under reduced 
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pressure. The resulting oil was filtered through a short column of silica gel using a 20-25% 
EtOAc-hexanes mixture as eluent to provide (15.75 g, 42.5%) of the compound as pale yellow 
oil.  
(1R, 2S)-1-((tert-Butoxycarbonyl)amino)-2-vinylcyclopropanecarboxylic acid 
 
To a solution of (1R, 2S)-ethyl 1-((tert-butoxycarbonyl)amino)-2-vinylcyclopropanecarboxylate 
(11.25 g, 44.1 mmol) in THF (33.3 mL) and MeOH (33.3 mL) was added to a solution of LiOH 
(7.87 g, 187.54 mmol). The resulting mixture was stirred at room temperature for 24 hours. The 
reaction mixture was separated using 1M NaOH (75 mL), water (75 mL) and EtOAc (90 mL). The 
mixture was shaken and the layers were separated using a separatory funnel. The organic layer 
was further extracted with 0.5M NaOH (75 mL). The combined aqueous portion was cooled to 0 
OC, acidified with 1 M HCl (~150 mL) and extracted with EtOAc (3 x 150 mL). The combined 
organic portion was washed with saturated aqueous NaCl solution, dried with Na2SO4, filtered 
and evaporated to dryness. This provides the acid as a light yellow gummy solid. The crude acid 
was dissolved in a 15% methanol-chloroform mixture and was evaporated with a high vacuum 
twice. The solid was then dissolved in chloroform and evaporated again under high vacuum. 
The gummy residue (10.51 g, 93.4%)was then used in the subsequent reaction.  
tert-Butyl (1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropylcarbamate 
 
A solution of acid (10.51 g, 46.24 mmol) and CDI (10.54 g, 65.0 mmol, 1.4 eq.) in anhydrous THF 
(115 mL) was heated at reflux for 1 h under dry nitrogen. The solution was cooled to room 
temperature. Then the solution was cooled to room temperature and transferred via cannula to 
a solution of cyclopropanesulfonamide (7.87 g, 65.0 mmol, 1.4 eq) in anhydrous THF (25 mL). 
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DBU (10.4 mL, 64.6 mmol, 1.4 eq) was added slowly to the resulting solution and stirring 
continued for 24 hrs. The reaction was quenched with 1N HCl to about pH of 1 and THF 
evaporated under reduced pressure. EtOAc was then used to extract the resulting suspension 
(3 x 350 mL); the combined organic portion was dried (Na2SO4), filtered, and evaporated to 
yield a yellowish solid. The crude material was purified by flash chromatography, eluting 3-8% 
acetone in CH2Cl2 to afford the compound as a white crystalline solid (10.96 g, 78%).  
(1R, 2S)-1-amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide hydrochloride 
 
Dichloromethane (5mL) was added to the product from the previous synthesis (0.41g, 1.234 
mmol), under nitrogen and stirred. TFA (5mL) was then added and stirring was continued for 2 
hours. The solvents were then evaporated under reduced pressure. The residue was treated 
with 4N HCl in 1,4-dioxane (2mL) and evaporated to dryness. The residue was then treated 
again with 4N HCl in 1,4-dioxane (2mL) and evaporated to dryness under a high vacuum. The 
resulting P1-P1’ amine-HCl salt was used as such in the following coupling reaction.   
6-Methoxyquinoxaline-2,3-diol 
 
A suspension of 4-methoxy-1, 2-phenylenediamine-2HCl (10 g, 47.4 mmol) in diethyloxalate 
(140 mL, 1.18 mmol, 25 eq) was treated with Et3N (13.25 mL, 94.8 mmol, 2 eq). The resulting 
thick slurry was heated to 150oC. Additional diethyloxalate (80 mL) was added to assist stirring 
of the thick suspension. After 3 h at 150oC, the reaction mixture was cooled to room 
temperature. The thick suspension was filtered, washed with water 4 times and EtOH 4 times to 
provide a pale green solid. The solid was air dried and then desiccated under high vacuum over 
night to yield the compound (8.1g, 89%) as a pale green solid.   
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3-Chloro-7-methoxyquinoxaline-2-ol 
 
To a thick slurry of the compound (7.45 g, 38.77 mmol), from the previous synthesis, in 
anhydrous DMF (40 mL) was slowly added SOCl2 (2.85 mL, 39 mmol) over 45 minutes. The 
reaction mixture gradually became less thick, the more SOCl2 was added. After the addition was 
complete, the reaction mixture was stirred at room temperature for 15 minutes and then 
heated to 110-115oC and stirred for 2 hours. The reaction mixture was then cooled to room 
temperature and an aqueous solution of 1 N HCl (100 mL) was added in one portion. The 
mixture was stirred for 30 minutes and the product precipitated. The precipitate was filtered 
and washed with water (4x) and Et2O (4x) to provide an olive green solid. The product was then 
air dried and desiccated overnight under high vacuum to yield an olive green solid (7.30 g. 
89%).  
(2R, 4S)-1-tert-butyl 2-methyl 4-(((4-bromophenyl)sulfonyl)oxy)pyrrolidine-1,2-dicarboxylate 
 
A solution of cis-proline (4 g, 16.31 mmol) in dry CH2Cl2 (30 mL) was cooled to 0
OC and then 
Et3N (11.3 mL, 81.061 mmol, 4.97 eq) was added slowly. After 15 minutes solid 4-Br-Ph-SOCl 
(8.34 g, 32.61 mmol, 2 eq) was added followed by the addition of DMAP (≈ 100 mg). The 
reaction mixture was then stirred at 30 minutes at 0OC and then stored in the refrigerator (5 OC) 
for 24 hours. The reaction mixture was slowly warmed to room temperature (ice water, cold 
water, water and then room temperature). Then it was diluted with CH2Cl2 and washed with 
saturated aqueous NaHCO3 solution and 10% aqueous citric acid solution. Organic phase was 
dried and evaporated. The product was purified by flash column chromatography to produce a 
light yellow gummy solid.   
(2R, 4R)-1-tert-butyl 2methyl 4-((3-chloro-7-methoxyquinoxaline-2-yl)oxy)pyrrolidine-1,2-
dicarboxylate 
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Half of the NMP (30 mL) was added to the quinoxaline under nitrogen and was stirred. Then 
CsCo3 (7.98 g, 24.51 mmol, 1.5 eq) was added and stirring continued. The other half of the NMP 
(30 mL) was added to the Bos-Proline-OMe and rotated at 40OC for 30 minutes. The resulting 
Bos-Proline-OMe solution was then added to the quinoxaline solution; it was then refluxed for 
over 24 hours. Flash column chromatography was then used to separate the layers at 15-20% 
EtOAc in hexanes to produce a yellow gummy solid.  
 (2S, 4R)-Methyl 4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate 
hydrochloride 
 
Dry CH2Cl2 (6 mL) and 4N HCl were added to the Boc-Proline under nitrogen. The resulting 
solution was stirred for 4 hours. After 4 hours the resulting solution was evaporated to dryness 
to produce the compound to be used in the next synthesis.  
(2S, 4R)-Methyl 1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-((3-chloro-7-
methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate 
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Boc-Tle-OH (0.5 g, 2.11 mmol, 1.3 eq) was added to the proline derivative (0.61 g, 1.63 mmol) 
under nitrogen and stirred. Both dry CH2Cl2 (10 mL) and dry DMF (7 mL) were added and the 
resulting solution was cooled to 0oC. At 0oC DIEA (1.62 mL, 9.78 mmol, 6.0 eq) was added and 
stirred for 15 minutes. Solid HATU (0.93 mL, 2.445 mmol) was added, stirred for 15 minutes and 
then the ice bath was removed. The solution was stirred over the weekend.  The solution was 
then washed with EtAc (50 mL), HCl (0. 25 M, 15 mL), Sodium bicarbonate (15 mL) and NaCl (15 
mL). Then the resulting mixture was high vacuumed to produce a thick red liquid (0.68 g, 
89.7%). 
(2S, 4R)-1-((S)-2-((tert-Butoxycarbonyl)amino)-3,3dimethylbutanol)-4-((3-chloro-7-
methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylic acid 
 
Under nitrogen, THF (6 mL) was added to C26H35ClN4O7 (0.68 g, 1.234 mmol). Water (6 mL) was 
then added to the mixture. The mixture was stirred, LiOH (0.16 g, 3.7026 mL, 3 eq) was added 
and stirring continued for 24 hours. Then 0.2 N HCl was added to the mixture until it reached a 
pH of 3. The solution was washed twice with both EtOH (2 x100mL) and then NaCl (20 mL). The 
solution was evaporated to dryness under high vacuum to produce a yellow gummy solid (0.70 
g, 97.1%).  
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Tert-Butyl ((S)-1-((2S, 4R)-4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)-2-(((1R,2S)-1-
((cyclopropylsulfornyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-
dimethyl-1-oxobutan-2-yl)carbamate 
 
Proline (0.70 g, 1.234 mmol) was added to the Boc (0.41 g, 1.234 mmol, 1 eq) under nitrogen 
and stirred. Dry DMF (10 mL) and dry DCM (7 mL) were added and the resulting mixture was 
cooled to 0OC. At 0OC DIEA (2.14 mL, 7.404 mmol, 6.0 eq) was added and stirring continued. 
HATU (1.23 g, 1.85 mmol, 1.5 eq) was then added, stirring continued for 15 minutes and ice was 
removed. The solution was stirred for 24 hours. After stirring overnight, the solution was 
washed with EtAc (100 mL), HCl (0.25 M, 30 mL), NaHCO3 (15 mL) and NaCl (15 mL). The 
solution was then evaporated to dryness under high vacuum. A column was run at 50% EtAc in 
hexanes to further purify the product, which was a yellow solid (0.63 g, 90%). 
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Results  
The purpose of this project was to modify the pre-existing compound MK-5172 and remove the 
side chain ring in order for it to fit better in the substrate envelope to minimize vulnerability to 
drug resistance, Figure 4. HCV drugs without a side chain ring are less hindered and therefore 
are more adaptable in fighting the mutant variants. A final compound was developed and 
synthesized. Instead of the side chain ring, the ring was removed and a chlorine atom was 
attached to the upper ring system; this enabled the molecule to fit better within the substrate 
envelope, Figure 5.  
Synthesis Evaluation 
The final compound was synthesized though a serious of steps involving the piecewise addition 
of smaller molecules. The initial six syntheses went according to plan producing a very efficient 
yield and there were no problems encountered in the actual lab work. Synthesis two, (±)-
(1R,2S)-Ethyl 1-((tert-butoxycarbonyl)amino)-2-vinylcyclopropanecarboxylate, had a low yield; 
this matched the yield seen in the assisting synthesis. However during the seventh synthesis, 6-
Methoxyquinoxaline-2,3-diol, problems arose. As the suspension was prepared, the mixture 
immediately turned into thick slurry that was difficult to work with. The hard to handle, slurry 
was then placed in a flask and stirred. The flask used was insufficient in containing the solution 
and it overflowed. Additional solvent was used to aid in mixing. Nevertheless the synthesis 
produced a decent yield. Additionally the eighth synthesis, (2R, 4S)-1-tert-butyl 2-methyl 4-(((4-
bromophenyl)sulfonyl)oxy)pyrrolidine-1,2-dicarboxylate, had problems with yield and so it 
had to be ran multiple times to produce enough product to move on to the next step. This was 
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a result of using a different brand of reagents than before, which greatly hindered the 
synthesis. Overall, the syntheses produced adequate yields. 
NMR 
After gaining the desired final compound, tests need to be run to ensure the validity of the 
compound that was experimentally created.  A nuclear magnetic resonance test was run on the 
final product to ensure that the functional groups were in the correct places and the product 
reflected the predicted one. A proton NMR is done with respect to hydrogen-1 nuclei. The 
spectrum produces peaks based on the location of hydrogen atoms in the molecule. It is run to 
ensure that the molecule has all of the function groups that it is predicted to have.  In the NMRs 
performed on the final product you will see the entire spectrum as a whole and two sections of 
it viewed from a closer perspective, Figures 6-8. This is done to see where and how many peaks 
there were in total, making the analysis of the NMR easier.  
NMR Assignments: 1H NMR (400 MHz, CDCl3) s, 1H), 7.8 (d, 1H), 7.25 (s, 5H), 7.2 (s, 
1H), 7.05 (s, 1H), 5.85 (s, 1H), 5.78 (m, 1H), 5.20 (m, 3H), 4.55 (t, 1H), 4.4 (d, 1H), 4.2 (d, 1H), 
4.15 (m, 1H), 3.98 (s, 3H), 2.14 (q, 1H), 1.98 (t, 1H), 1.65 (s, 2H), 1.48 (m, 1H), 1.32 (s, 12H), 1.04 
(s, 12H).    
The peak in the 10.1 ppm region represents a COH bond, at 7.8-7.0 ppm region are the 
aromatic and amide hydrogen and in the 6.0-5.0 ppm region are the hydrogen on the Boc 
group. The peaks in the 4.0 ppm represent esters, the 2.0 ppm region ketones and nitro groups, 
and in the 1.0-2.0 ppm region are the saturated alkanes, alcohols and double bonds. As a whole 
the NMR supports the location of the hydrogens on the predicted final product, verifying it to 
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match the predicted molecule. Additional testing needs to be run on the final product, such the 
enzymatic test run on MK-5172. This is done to fully ensure the final product is the desired 
compound.  
Enzymatic Assay 
Tests were run on MK-5172, Figure 9 and compared to various drugs on the market or in phases 
against the wild type of the virus and three of the drug resistant variants. Against the wild type 
MK-5172 produced low Ki values. Ki is the dissociation constant for inhibitor binding and 
therefore the lower the Ki, the more beneficial the protease inhibitor. Additionally MK-5172 
produced excellent results against the drug-resistant variants, which is important because the 
mutants are so variable. Finding a compound that is able to combat three of the most common 
mutant sites is very essential in creating a worthy drug for HCV. The results of those tests 
showed that MK-5172 was superior at combating the virus compared to the other drugs. The 
lower the enzymatic activity, the more efficient the drug is in combating the virus directly.  
Therefore it can be predicted that in switching the side chain ring to a chlorine atom would 
simultaneously produce more enhanced results against the drug resistant variants; tests still 
need to be run to verify this prediction. These tests would involve the same ones run for the 
MK-5172 drug.    
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Conclusions 
The purpose of this project was to modify the functional groups on the MK-5172 drug and 
remove the side chain ring. This was done in order for the drug to fit better within the substrate 
envelope of the virus and to minimize vulnerability to drug resistance; other HCV drugs without 
a side chain ring have shown to be more adaptable in fighting the mutant variants. As a result 
of this project a new MK-5172 derivative was developed; the compound is predicted to produce 
more efficient results against both the virus itself and its mutant variants. The derivative is 
smaller than the original compound, therefore is predicted to fit easier in the substrate 
envelope and protect more proficiently against drug resistance. In future studies it would be 
beneficial to exchange the chlorine atom with other groups of atoms, such as methyl, ethyl or 
amine groups, Figure 10. Also, by changing the functional groups on a molecule it can have 
positive or negative effects on inhibition. Hence, it is the hope that this new derivative 
produces positive inhibition effects.  
In the future, new derivatives and analogs should be tested to see their efficacy against HCV, in 
hopes that one of them will eliminate the virus all together. This can be done by exchanging the 
functional groups on pre-existing drugs, or by creating new drugs all together by combining the 
portions of previous ones that are the most effective. Drugs that are able to fit in the substrate 
envelope will produce the best results; inhibitors that bind to the NS3-NS4A proteins will also 
produce results. Standard testing such as NMR and an enzymatic kinetic evaluation should be 
run on the drugs that are the most promising in order to move them further into the drug 
design phases and eventually on to the market.  
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The hope, after synthesizing a drug to eliminate HCV, would be to create one that has the 
capability to eliminate HIV simultaneously. In doing this people who have both diseases would 
be able to get a concise, operational drug; combining drugs is a difficult task but once it is 
created patients will have a lot simpler, safer treatment. Treatments should not be the only 
type of drug used to combat these viruses. Prevention drugs need to be created once a solution 
to the treatment of the virus is synthesized. Once drugs are capable of preventing a virus, the 
virus becomes a thing of the past and can no longer harm people.  
Additionally in working with difficult to culture diseases, such as HCV, new techniques should 
be created that can be universally used for other disease. It should be the goal when techniques 
are difficult to use in drug design, new ones should be found in order to prevent that problem 
from happening in the future.  
Difficult to solve viruses, like HCV, should drive scientists to work hard to create a solution to 
the problem. The more difficult the disease is in solving, the more interesting the solution that 
comes out of it. In working with a difficult disease, new techniques arise that can be beneficial 
to others along the line. Additionally it is amazing creating massive molecules and drugs out of 
simple functional groups. Scientists are able to create a drug to eliminate a harmful virus, by 
the addition of small molecules; this in itself is an incredible concept.  
Hopefully scientists will continue to work hard at creating a new drug to eliminate HCV 
altogether.  
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Appendix 
 
Figure 1 HCV structure: HCV enclosing a single stranded RNA of 9.6 kb. The genome carries a 
single long open reading frame (ORF) which on processing forms a polyprotein that is 
proteolytically cleaved into distinctive products. The HCV polyprotein is cleaved co- and 
posttranslationally by cellular and viral proteinases into 10 different products, with the 
structural proteins located in the amino- terminal one-third and the nonstructural (NS) 
replicative proteins in the rest. NS3/NS4A have been focused on in particular. (Rehman, 2011)  
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Figure 2: A portion of the drugs in phases and in the market that directly affect HCV. As you can 
see Merck’s approved product is Victrelis, Boceprevir. Every drug has to undergo a series of 
phases and testing before it reaches the market. The above figure shows some of the drugs 
undergoing this process. MK-5172 is another drug created by the Merck Company. The benefits 
in making the MK-5172 drug is that it has shown better potential in combating drug-resistant 
variants than Boceprevir. (HCV drugs). 
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Figure 3: MK-5172; as shown the side chain is the line connecting the top of the molecule to the 
bottom. In that side chain elimination it is predicted to increase the efficacy against the virus, 
by fitting well within the substrate envelope.  
 
Figure 4: Drugs along with their derivatives. MK-5172 is shown along with the final compound 
demonstrated as the first derivative and the R group being a chlorine atom. Side chains are 
manipulated, focusing on minimizing the size of the compounds.
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Figure 5: Final step in the drug synthesis. In the original MK-5172 molecule the location of the 
chlorine atom would be attached to the lower Boc group. The elimination of the side chain ring 
is predicted to produce better results against the virus and the drug resistant variants. 
 
Figure 6: Full Proton NMR spectrum for the final product. The NMR shows peaks where the 
hydrogen are located on the final compound. 
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Figure 7: Proton NMR from the 6.2 - 3.6 ppm region. A closer look allows for better 
interpretation of the NMR peaks.   
 
Figure 8: Proton NMR from the 2.2 – 0 ppm region. Again a closer look enables the view to see 
the peaks in an enhanced fashion. 
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Figure 9: Activity against wild-type and drug resistant variants. MK-5172 produced the lowest Ki 
values as compared to the wild type virus and drug resistant variants; the lower the Ki the more 
effective the drug is in combating the virus (Akbar Ali).  
 
Figure 10: Final product exchanged to a new drug derivative involving other side groups, 
represented by R. The R groups would be functional groups smaller than a ring system such as 
methyl, ethyl or amine groups. The ring system has trouble fitting in the substrate envelope 
decreasing the efficacy of the drug, therefore the smaller the functional groups the better the 
drug.   
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